Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.56 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583047 | 1.00 | PARP10 (0.56) | PARP10PARP1HTR2CHTR2ADRD2 | |
| SCHEMBL29622425 | 0.88 | PYGL (0.49) | PARP10PARP1HTR2CHTR2AGFER | |
| SCHEMBL3112268 | 0.88 | PYGL (0.49) | PARP10PARP1HTR2CHTR2AGFER | |
| Hydrochloric Acid SCHEMBL30142485 | 0.86 | PYGL (0.48) | PARP10PARP1HTR2CHTR2AGFER | |
| Hydrochloric Acid SCHEMBL2144161 | 0.86 | PYGL (0.48) | PARP10PARP1HTR2CHTR2AGFER | |
| SCHEMBL5467312 | 0.86 | PYGL (0.45) | PARP10PARP1HTR2CHTR2AGFER | |
| SCHEMBL549063 | 0.83 | DRD2 (0.59) | PARP10PARP1HTR2CHTR2ADRD2 | |
| SCHEMBL23188859 | 0.81 | PARP10 (0.56) | PARP10PARP1HTR2CHTR2ASMN1; SMN2 | |
| SCHEMBL9081400 | 0.81 | PARP1 (0.44) | PARP10PARP1HTR2CHTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL17799458 | 0.81 | DRD2 (0.57) | PARP10PARP1HTR2CHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115353478-A | Preparation method of indole compound | 南京工业大学 | 2022-11-18 | — | — | CN | claimed |
| WO-2026103853-A1 | TSHR ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4301739-B1 | FPR2 (FORMYL PEPTIDE RECEPTOR 2) RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF THE AUTISM SPECTRUM DISORDER | UNIV DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119822910-A | Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal | 延安大学 | 2025-04-15 | — | — | CN | disclosed |
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
| US-5981752-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5773618-A | PYRROLOQUINOLINONE DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0807631-A1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| US-4904684-A | 2-(4,5-dihydro-1H-imidazol-2-yl)-1,2,4,5-tetrahydropyrrolo[3,2,1-hi]indole derivatives useful as antidiabetic agents | SYNTHELABO (FR) | 1990-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | PARP10 4220/4885PARP1 3068/4885HTR2C 1972/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | PARP10 810/4885PARP1 1017/4885HTR2C 2173/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PARP10 705/4885PARP1 307/4885HTR2C 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.